AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (linagliptin)
Description: once daily for 28 days
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (linagliptin)
Description: once daily for 28 days
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily for 28 days
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: once daily for 28 days
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sitagliptin)
Description: once daily for 28 days
Study NCT00716092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 5mg once daily for 28 days
Study NCT04606277 — intervention group
Intervention type: OTHER
Intervention: Smartphone addiction scale, physical activity scale and depression questionnaire
Description: Telephone addiction of the subjects was measured. Then, physical activity levels were questioned, and finally depression scale was applied.
Study NCT03802864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
Study NCT03802864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bupivacaine
Description: After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
Study NCT03496519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Durvalumab and Trabectedin
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2
Study NCT03496519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion of Durvalumab and Trabectedin
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
Study NCT03627884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate Catheter Lock Solution
Description: Using Sodium Bicarbonate Catheter Lock Solution
Study NCT03627884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Catheter Lock Solution
Description: Using Sodium Bicarbonate Catheter Lock Solution
Study NCT01509781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of suction drain(s) following mastectomy
Description: One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
Study NCT01509781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive skin sutures.
Description: Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
Study NCT02370433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Neostigmine and Glycopyrrolate
Study NCT02370433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Neostigmine and Glycopyrrolate
Study NCT00846105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid MRSA PCR test for screening carriers
Description: In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
Study NCT00846105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid MRSA PCR test for screening carriers
Description: In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
Study NCT00801801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Sorafenib
Description: Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
Study NCT02230956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
Study NCT02230956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injection into the intra-articular space of the study knee.
Study NCT04413292 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Description: expression analysis of biomarkers
Study NCT04111250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary sinus augmentation
Description: Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
Study NCT00307749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for 24 weeks
Study NCT00307749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 20mg, once daily for 24 weeks
Study NCT00307749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 40mg, once daily for 24 weeks
Study NCT00307749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-257
Description: 80mg, once daily for 24 weeks
Study NCT01843998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.1% Ointment
Description: Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
Study NCT01078480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation using a precontoured titanium plate and screws
Description: Operation using a precontoured titanium plate and screws
Study NCT01078480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Displaced midshaft fracture of the collar bone
Description: Displaced midshaft fracture of the collar bone treated with an arm sling
Study NCT03164980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectidin (Yondelis)
Description: To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 Zibotentan
Description: 10 mg oral tablets once daily
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 IV on day 1 every 3 weeks
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 IV on day 1 every 3 weeks
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
Study NCT00929162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for ZD4054 10 mg
Study NCT00213655 — intervention group
Intervention type: BIOLOGICAL
Intervention: bladder tumor recurrence
Description: bladder tumor recurrence assessed by clinical and biological exams
Study NCT03738202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention package
Description: Multifaceted intervention package will comprise following strategies:~1. Initial training for all workers and managers on occupational health and safety (OHS)~2. Follow-up refresher sessions every three months~3. Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~4. Provision of adequate supplies of face masks to support the health and safety plan
Study NCT04352478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathological result
Description: Incidental gallbladder cancer and other pathology
Study NCT01893385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D (drug)
Study NCT01893385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D (drug)
Study NCT00868465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine
Description: Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
Study NCT00868465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
Study NCT03945539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
Study NCT01217476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study NCT03945539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
Study NCT04636658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometer training
Description: Incentive spirometer training 5 sessions a week, each session of 15 minutes, for 4 weeks
Study NCT04636658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic resistance exercises
Description: Incentive spirometer with diaphragmatic resistance exercises. Resistance is applied through the different Thera bands and then performing the pursed lip breathing exercise. Resistance increased weekly as per tolerance by the patient.~Digital spirometer training for 15 minutes. diaphragm breathing exercises with resistance for 30 minutes. 5 sessions a week, for 4 weeks
Study NCT03911648 — intervention group
Intervention type: DRUG
Intervention: 0.5 ml.kg-1 bupivacaine 0.25%
Description: Caudally
Study NCT03911648 — intervention group
Intervention type: DRUG
Intervention: 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%
Description: Caudally
Study NCT01701414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block: 25 mL of 0.5% bupivacaine
Description: 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
Study NCT04301063 — intervention group
Intervention type: OTHER
Intervention: RV3278A
Description: RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
Study NCT01701414 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo: 3cc of 0.9% Normal Saline
Description: 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
Study NCT01758835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint 3 weeks
Description: A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
Study NCT01758835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast 3 weeks
Description: A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
Study NCT01758835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cast 6 weeks
Description: standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
Study NCT04214548 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT01217476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study NCT02037191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
Study NCT02037191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day
Study NCT04290715 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03567005 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A digital contact lenses
Description: Silicone hydrogel digital contact lenses
Study NCT00262769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
Study NCT04890535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TBAJ-587
Description: oral suspension
Study NCT04317625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI scanning
Description: The patients whose PSA levels are between 2.5 and 4.0ng/ml will be recommended to mpMRI scanning at first but not biopsy or active surveillance.
Study NCT01059071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID
Study NCT01059071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
Study NCT03635853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug containing extract from cock's comb
Description: a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
Study NCT04259606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cassia Cinnamon
Description: Reddish - brown to light brown, typical sweet and aromatic free flowing powder.
Study NCT04259606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcined magnesia
Description: White, odor, color and flavorless thin powder.
Study NCT01957683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCLIPs™ Family of Products
Description: Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
Study NCT00444795 — intervention group
Intervention type: DRUG
Intervention: Sunitinib malate
Description: Sunitinib : dosing not pre-determined
Study NCT00444795 — intervention group
Intervention type: DRUG
Intervention: sunitinib malate
Description: Sunitinib : dosing not pre-determined
Study NCT03567005 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses
Description: Silicone hydrogel spherical contact lenses
Study NCT04890535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo oral suspension for TBAJ-587
Study NCT02770651 — intervention group
Intervention type: DEVICE
Intervention: Everolimus-Eluting stent
Description: Everolimus-Eluting stent with bioabsorbable polymer
Study NCT02770651 — intervention group
Intervention type: DEVICE
Intervention: Zotarolimus-Eluting stent
Description: Zotarolimus-Eluting stent with permanent polymer
Study NCT03839342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: MEK inhibitor, 45mg oral tablet
Study NCT03839342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: BRAF inhibitor, 450mg oral capsule
Study NCT02346019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial thighplasty with or without thigh liposuction
Description: Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
Study NCT00262769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
Study NCT03902145 — intervention group
Intervention type: OTHER
Intervention: Egg
Description: One egg per day for 6 months
Study NCT01536535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
Study NCT01536535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Corticosteroid
Description: Treatment with IV Corticosteroid
Study NCT02598986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Macronutrient supplementation
Description: adding of phosphorus, potassium and magnesium
Study NCT02598986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Macronutrient supplementation
Description: adding of phosphorus, potassium and magnesium
Study NCT00783380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients